Match!
M. Horváth
11Publications
3H-index
16Citations
Publications 11
Newest
#1Bertalan NémethH-Index: 4
#2R. BendesH-Index: 1
Last.Zoltán Kaló (ELTE: Eötvös Loránd University)H-Index: 18
view all 9 authors...
Abstract Objectives The aim was to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary. Methods To assess the cost-effectiveness of cariprazine, a deterministic 8-health state Markov cohort model was built. The analysis was performed from a third-party payer perspective. Data were gathered from relevant sources of the scientific literature and public databases. Unit costs were b...
Source
#1A.N. Fasseeh (ELTE: Eötvös Loránd University)H-Index: 1
#2Bertalan NémethH-Index: 4
Last.Z. Kaló (ELTE: Eötvös Loránd University)H-Index: 2
view all 8 authors...
1 CitationsSource
#1Bertalan NémethH-Index: 4
#2R. BendesH-Index: 1
Last.Zoltán VokóH-Index: 21
view all 13 authors...
1 CitationsSource
#1Bertalan NémethH-Index: 4
#2Ahmad FasseehH-Index: 1
Last.Balázs Nagy (ELTE: Eötvös Loránd University)H-Index: 6
view all 8 authors...
ABSTRACTIntroduction: There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia.Areas covered: A systematic review on studies describing health economic models in schizophrenia and a targeted literature review on utility mapping algorithms in schizophrenia were carried out. Models found in the review were collated and assessed in detail according to their type and various other attributes. ...
4 CitationsSource
#1Gabor G. KovacsH-Index: 52
#2T. AlmásiH-Index: 1
Last.A. Zemplényi (PTE: University of Pécs)H-Index: 2
view all 9 authors...
Abstract Purpose To provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs. Methods Studies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017. Results Twenty-three studies, from the 1075 references ini...
2 CitationsSource
#1Bertalan NémethH-Index: 1
#2A MolnarH-Index: 2
Last.Zoltán Vokó (ELTE: Eötvös Loránd University)H-Index: 21
view all 8 authors...
Aim: Our study aimed at estimating differences in quality-adjusted life year (QALY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone. Materials & methods: A Markov model was built, based on the Mohr–Lenert approach and data derived from clinical trials, to estimate potential QALY gains of patients. Results: Patients had higher probability of reaching better health states treated with cariprazine compared with risperidone. In...
5 CitationsSource
#1Bertalan NémethH-Index: 4
#2A.N. FasseehH-Index: 1
Last.Balázs Nagy (ELTE: Eötvös Loránd University)H-Index: 6
view all 7 authors...
Source
#1G KovácsH-Index: 1
#2T. AlmásiH-Index: 1
Last.A. ZemplényiH-Index: 2
view all 9 authors...
Source
Source
#2Bertalan NémethH-Index: 4
Last.Zoltán Kaló (ELTE: Eötvös Loránd University)H-Index: 18
view all 7 authors...
Source
12